Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Everest Medicines Ltd. ( (HK:1952) ) just unveiled an update.
Everest Medicines Ltd. has announced a board meeting scheduled for August 28, 2025, to consider and approve the interim results for the first half of the year. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$48.32 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
More about Everest Medicines Ltd.
Everest Medicines Ltd. is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in the Asian market.
Average Trading Volume: 7,348,086
Technical Sentiment Signal: Buy
Current Market Cap: HK$25.02B
Find detailed analytics on 1952 stock on TipRanks’ Stock Analysis page.